The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Commentary|Slideshows|May 14, 2025
3 Perspectives on Medical Research Funding Cuts
Author(s)Andy Studna, Senior Editor
Industry leaders share their thoughts on the NIH funding cuts and how they are impacting clinical research.
Advertisement
The calendar year of 2025 has brought many new challenges to the clinical research industry. Earlier in the year, several key executive orders issued by President Donald J. Trump put the industry at a crossroads. In addition to scaling back on diversity initiatives, President Trump took steps to cut funding for medical research, which has greatly impacted clinical trials conducted by academic institutions.
In February, the National Institutes of Health (NIH)
In a video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, said:“Things have definitely changed. I think that funding is now the biggest issue regarding the future of research. People need to get used to the idea of shifting from relying on federal grants for funding to exploring other possible sources.”
In light of these challenges posed by the current administration, Applied Clinical Trials (ACT)has spoken with several leaders in the clinical research industry to gain insight. In this slideshow, Lanton, along with Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), and Iddo Peleg, CEO and co-founder at Yonalink, each share their thoughts on the medical research funding cuts and how the industry can effectively move forward with them still in place.
Image Credit: © Tada Images - stock.adobe.com
Advertisement
Related to this article
In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.
Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.
A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
5